Roche sees no Brexit interruption for patients

Roche holding ag ceo says sales growth for hemlibra primarily driven by non-inhibitors patients Roche holding ag ceo says spark therapeutics acquisition planned to be completed in first half Roche holding ag ceo says still believes biosimilars will enter market in u.s. In second half Roche holding ag says sees continued "very strong" growth for ocrevus after entry of novartis's mayzent Roche holding ag drugs chief says gantenerumab for alzheimers remains a high risk

from Reuters: Company News https://reut.rs/2KJBKCX
via IFTTT